Keros Board Best Equipped to Oversee Strategic Review Process and Execute on Ultimate Outcome of that Process ADAR1’s Disruptive and Self-Serving Campaign Stands to Jeopardize the Future Value ...

Keros Therapeutics urges stockholders to vote for its director nominees amid ADAR1's campaign, emphasizing board qualifications and strategic review. Keros Therapeutics, a clinical-stage ...

ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics ...

Keros Therapeutics, Inc. issued a statement addressing misleading claims made by ADAR1 Capital Management ahead of its upcoming 2025 Annual Meeting of Stockholders on June 4, 2025. Keros' Board is ...

Keros Therapeutics, Inc. has a 1-year low of $9.12 and a 1-year high of $72.37. The stock’s fifty day simple moving average is $12.70 and its 200 day simple moving average is $21.23.

Urges Stockholders to Protect the Value of Their Investment by Voting “FOR” Each of the Company’s Highly Qualified Director Nominees LEXINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Keros ...

LEXINGTON, Mass. - Keros Therapeutics, Inc. (NASDAQ:KROS), a clinical-stage biopharmaceutical company, announced today that Glass Lewis & Co., a leading independent proxy advisory firm ...

Keros Therapeutics shareholder ADAR1 Capital Management said it plans to withhold votes for board members Mary Ann Gray and Alpna Seth. "ADAR1 calls for Keros to restructure the business ...

April 10 (Reuters) - Keros Therapeutics (KROS.O), opens new tab has adopted a poison pill defense to fend off hostile takeovers, after some investors indicated a desire to influence the control of ...